Please Wait
Applying Filters...
Menu
$ API Ref.Price (USD/KG) : 78,477Xls
Filters Filter
Cross PopUp
FILTER :

filter clear-filterReset all filters

01 68NOVARTIS

filter clear-filterReset all filters

filter clear-filterReset all filters

filter clear-filterReset all filters

filter clear-filterReset all filters

PharmaCompass

01

arrow
American Pharma Summit
Not Confirmed
arrow
American Pharma Summit
Not Confirmed

DABRAFENIB MESYLATE

US Patent Number : 8835443

Drug Substance Claim :

Drug Product Claim :

Application Number : 202806

Patent Use Code : U-2027

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2025-06-10

blank

02

arrow
American Pharma Summit
Not Confirmed
arrow
American Pharma Summit
Not Confirmed

DABRAFENIB MESYLATE

US Patent Number : 8835443

Drug Substance Claim :

Drug Product Claim :

Application Number : 202806

Patent Use Code : U-2298

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2025-06-10

blank

03

arrow
American Pharma Summit
Not Confirmed
arrow
American Pharma Summit
Not Confirmed

DABRAFENIB MESYLATE

US Patent Number : 8835443

Drug Substance Claim :

Drug Product Claim :

Application Number : 202806

Patent Use Code : U-2026

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2025-06-10

blank

04

arrow
American Pharma Summit
Not Confirmed
arrow
American Pharma Summit
Not Confirmed

DABRAFENIB MESYLATE

US Patent Number : 9233956

Drug Substance Claim :

Drug Product Claim :

Application Number : 202806

Patent Use Code : U-2032

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2029-05-04

blank

05

arrow
American Pharma Summit
Not Confirmed
arrow
American Pharma Summit
Not Confirmed

DABRAFENIB MESYLATE

US Patent Number : 9233956

Drug Substance Claim :

Drug Product Claim :

Application Number : 202806

Patent Use Code : U-2296

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2029-05-04

blank

06

arrow
American Pharma Summit
Not Confirmed
arrow
American Pharma Summit
Not Confirmed

DABRAFENIB MESYLATE

US Patent Number : 7994185

Drug Substance Claim : Y

Drug Product Claim : Y

Application Number : 202806

Patent Use Code : U-2296

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2030-01-20

blank

07

arrow
American Pharma Summit
Not Confirmed
arrow
American Pharma Summit
Not Confirmed

DABRAFENIB MESYLATE

US Patent Number : 7994185

Drug Substance Claim : Y

Drug Product Claim : Y

Application Number : 202806

Patent Use Code : U-2032

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2030-01-20

blank

08

arrow
American Pharma Summit
Not Confirmed
arrow
American Pharma Summit
Not Confirmed

DABRAFENIB MESYLATE

US Patent Number : 7994185

Drug Substance Claim : Y

Drug Product Claim : Y

Application Number : 202806

Patent Use Code : U-1406

Delist Requested :

Patent Use Description : TREATMENT OF MELANOMA

Patent Expiration Date : 2030-01-20

blank

09

arrow
American Pharma Summit
Not Confirmed
arrow
American Pharma Summit
Not Confirmed

DABRAFENIB MESYLATE

US Patent Number : 8703781

Drug Substance Claim : Y

Drug Product Claim : Y

Application Number : 202806

Patent Use Code : U-2296

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2030-10-15

blank

10

arrow
American Pharma Summit
Not Confirmed
arrow
American Pharma Summit
Not Confirmed

DABRAFENIB MESYLATE

US Patent Number : 8703781

Drug Substance Claim : Y

Drug Product Claim : Y

Application Number : 202806

Patent Use Code : U-1713

Delist Requested :

Patent Use Description : TAFINLAR IN COMBINATIO...

Patent Expiration Date : 2030-10-15

blank